Product Information
JOURNAVX 50 MG TABLET is a brand product labeled by Vertex Pharmaceuticals Incorporated, priced at $15.4130 per EA under NDC 51167054830. Its NADAC has been published 68 times since Jun 18, 2025.
FDA first approved this application on Jan 30, 2025.
Strength
50 mg/1
Manufacturer
Vertex Pharmaceuticals IncorporatedNDC
51167054830
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
7/1/2026
Active Ingredients
SUZETRIGINEApproval Type
New Drug (NDA)
FDA Application
NDA219209FDA Approved
1/30/2025
On Market Since
1/30/2025
Pharmacological Classes
Price Statistics
The NADAC for JOURNAVX 50 MG TABLET has been published 68 times since Jun 18, 2025, and over the history we have for it it has risen 3.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.4130 per EA |
|---|---|
| All-time high | $15.4130 (Sep 30, 2026) |
| All-time low | $14.8386 (Jun 17, 2026) |
| 52-week high | $15.4130 |
| 52-week low | $14.8386 |
| Median price | $14.8514 |
| Average price | $14.9560 |
| Largest weekly change | +3.9% (Jul 8, 2026) |
| Weeks tracked | 68 |
| Tracking since | Jun 18, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Vertex Pharmaceuticals Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Suzetrigine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of JOURNAVX 50 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for JOURNAVX 50 MG TABLET, manufactured by Vertex Pharmaceuticals Incorporated, is $15.4130 per EA (NDC 51167054830), effective Sep 30, 2026.
How has the price of JOURNAVX 50 MG TABLET changed over time?
Over the history we have for it, the NADAC for JOURNAVX 50 MG TABLET has risen 3.8%. It has been tracked across 68 weekly CMS publications since Jun 18, 2025.
What are the highest and lowest recorded NADAC prices for JOURNAVX 50 MG TABLET?
Since Jun 18, 2025, the NADAC for JOURNAVX 50 MG TABLET has ranged from a low of $14.8386 (Jun 17, 2026) to a high of $15.4130 (Sep 30, 2026), with a median of $14.8514 per EA.
Are there cheaper alternatives to JOURNAVX 50 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as JOURNAVX 50 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures JOURNAVX 50 MG TABLET?
JOURNAVX 50 MG TABLET (NDC 51167054830) is labeled by Vertex Pharmaceuticals Incorporated, and CMS classifies it as a brand product.